Literature DB >> 28604846

Identification of active components in Yixinshu Capsule with protective effects against myocardial dysfunction on human induced pluripotent stem cell-derived cardiomyocytes by an integrative approach.

Minyu Zhang1, Hongwei Wu2, Feifei Guo2, Yangyang Yu3, Junying Wei2, Ya Geng4, Shifeng Wang5, Shiyou Li3, Hongjun Yang2.   

Abstract

Traditional Chinese medicine (TCM) preparations have significant effects on some refractory diseases; however, these compositions are complex and their mechanisms are unknown. Identification of the active components in these preparations is essential. The mortality rate for heart failure (HF) has been increasing in recent years, and myocardial dysfunction (MD) has been proved to be the pathological basis of HF. Yixinshu Capsule (YXSC) is a multi-component oral drug with therapeutic effects on HF. However, the key active components are still unclear. In this study, YXSC intestinal absorption liquid (IAL) was used and 62 compounds were identified by an analytical chemistry approach. Then, a compound - target - function network was established with a bioinformatics analysis tool. Finally, a cell model of MD on human-induced pluripotent stem cell-derived cardiomyocytes (hiPS-CMs) was used to verify the therapeutic effects of the active components of YXSC. Schisandrin A (Sch A) and schisandrin B (Sch B) were demonstrated to be the active components of YXSC by attenuating endothelin-1 (ET-1)-induced contraction dysfunction, brain natriuretic peptide (BNP) content elevation, and the morphological changes of hiPS-CMs. For the first time, our data illustrate the potent protective effects of Sch A and Sch B on ET-1-induced dysfunctional hiPS-CMs and revealed their effective targets and pathways. The integrative approach used in our study was applied to identify active components in TCM preparations and excavate the possible mechanisms.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28604846     DOI: 10.1039/c6mb00813e

Source DB:  PubMed          Journal:  Mol Biosyst        ISSN: 1742-2051


  11 in total

1.  Traditional Chinese medicine for acute coronary syndrome: A meta-analysis of clinical manifestations and objective indicators.

Authors:  Jiangquan Liao; Tao Li; Yingying Hua; Mingjing Shao; Yan Wang; Zhe Wang; Kangkang Wei; Jiangmeng Chang; Xiaoqiong Zhang; Ming Chen; Xianlun Li; Jinhang Du
Journal:  Medicine (Baltimore)       Date:  2021-08-20       Impact factor: 1.817

2.  Yixin-Shu facilitated cardiac-like differentiation of mesenchymal stem cells in vitro.

Authors:  Jingjing Zhang; Feifei Guo; Hongwei Wu; Junying Wei; Minghua Xian; Fangfang Fan; Shihuan Tang; Ye Zhao; Yi Zhang; Defeng Li; Hongjun Yang
Journal:  RSC Adv       Date:  2018-03-12       Impact factor: 4.036

3.  DanHong injection targets endothelin receptor type B and angiotensin II receptor type 1 in protection against cardiac hypertrophy.

Authors:  Min-Yu Zhang; Fei-Fei Guo; Hong-Wei Wu; Yang-Yang Yu; Jun-Ying Wei; Shi-Feng Wang; Yu-Xin Zhang; Ming-Hua Xian; Qing-Hua Wu; Bu-Chang Zhao; Shi-You Li; Hong-Jun Yang
Journal:  Oncotarget       Date:  2017-10-13

Review 4.  Schisandra chinensis Fructus and Its Active Ingredients as Promising Resources for the Treatment of Neurological Diseases.

Authors:  Minyu Zhang; Liping Xu; Hongjun Yang
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

5.  Chinese Patent medicine to treat a 32-year-old man with sinus bradycardia and cardiac sinus arrests: A case report.

Authors:  Dong Yan; Xiang-Ru Xu; Yu-Liang Qian; Hai-Yan Peng; Hui Qian; Bo-Wen Yue; Li-Li Zhao; Zi-Han Zhang; Zhu-Yuan Fang
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

6.  Yixinshu capsule combined with conventional treatment for chronic heart failure: Protocol for a systematic review and trial sequential analysis.

Authors:  Yinhe Cai; Qingsong Zhang; Cihui Huang; Ke Lu; Baishu Chen; Cuiling Liu
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

7.  Yixin-Shu Capsules Ameliorated Ischemia-Induced Heart Failure by Restoring Trx2 and Inhibiting JNK/p38 Activation.

Authors:  Changpei Xiang; Fangbo Zhang; Jinhuan Gao; Feifei Guo; Mao Zhang; Rui Zhou; Junying Wei; Ping Wang; Yi Zhang; Jingjing Zhang; Hongjun Yang
Journal:  Oxid Med Cell Longev       Date:  2021-02-16       Impact factor: 6.543

Review 8.  The potential of plant extracts in cell therapy.

Authors:  Caifeng Li; Zhao Cui; Shiwen Deng; Peng Chen; Xianyu Li; Hongjun Yang
Journal:  Stem Cell Res Ther       Date:  2022-09-14       Impact factor: 8.079

Review 9.  Methodology of network pharmacology for research on Chinese herbal medicine against COVID-19: A review.

Authors:  Yi-Xuan Wang; Zhen Yang; Wen-Xiao Wang; Yu-Xi Huang; Qiao Zhang; Jia-Jia Li; Yu-Ping Tang; Shi-Jun Yue
Journal:  J Integr Med       Date:  2022-09-22

10.  Integrated UPLC-Q/TOF-MS Technique and MALDI-MS to Study of the Efficacy of YiXinshu Capsules Against Heart Failure in a Rat Model.

Authors:  Jing Xu; Xianyu Li; Fangbo Zhang; Liying Tang; Junying Wei; Xiaoqing Lei; Huanhuan Wang; Yi Zhang; Defeng Li; Xuan Tang; Geng Li; Shihuan Tang; Hongwei Wu; Hongjun Yang
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.